EPIX is focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. Using its proprietary drug discovery technology and approach, EPIX has advanced four drug candidates into clinical trials and has additional programs in preclinical development and discovery. EPIX has three clinical-stage drug candidates: PRX-03140 for the treatment of Alzheimer's disease, which is currently in two Phase 2b clinical trials - one in combination with Aricept® and the other is a monotherapy trial; PRX-08066 for the treatment of pulmonary hypertension (PH) and PH associated with chronic obstructive pulmonary disease, which is currently in a Phase 2b trial; and PRX-07034, which completed a Phase 1b trial in April 2007 and has potential in the treatment of cognitive impairment associated with schizophrenia. The company also has MS-325 (formerly marketed as Vasovist®, gadofosveset trisodium, by Bayer Schering Pharma), a novel contrast agent designed to provide improved imaging of the vascular system using magnetic resonance angiography (MRA).